Cancer immunotherapy targeting mesothelin represents a potentially plausible approach for the control of ovarian cancer as most ovarian cancers express high levels of mesothelin. In the current study, we created a mesothelinpositive luciferase-expressing ovarian cancer model, MO-SEC/luc. This luciferase-expressing tumor model allowed us to quantitate tumor distribution and tumor load in tumorchallenged mice using a non-invasive bioluminescence imaging system. In addition, we identified an H-2D b -restricted mesothelin peptide-specific cytotoxic T-lymphocyte (CTL) epitope (amino acid (aa) 406-414) that was endogenously processed and presented by MOSEC/luc tumor cells. We showed that adoptive transfer of mesothelin peptide (aa406-414)-specific CD8 + T cells led to the control of MOSEC/luc tumor cells. The MOSEC/luc tumor model and the newly identified H-2D b -restricted murine mesothelin-specific CTL epitope (aa406-414) will be very useful for the development of immunotherapy for ovarian cancer as well as for the development of quantitative CD8 + T cell-mediated immunological assays.
Introduction
Metastatic ovarian cancer is extremely difficult to cure and is responsible for the highest mortality rate among patients with gynecologic malignancies. Current efforts to reduce this mortality rate, including improvement of early detection and treatment, have been relatively unsuccessful. Existing standard therapies for advanced disease such as primary cytoreductive surgery followed by chemotherapy rarely result in long-term benefits for patients with locally advanced and metastatic disease. [1] [2] [3] Thus, identification of alternative approach to control ovarian cancer is an urgent concern.
Immunotherapy represents a potentially plausible approach for the control of ovarian cancer. The ideal cancer therapy should have the potency to eradicate systemic tumors and control metastases as well as the specificity to discriminate between malignant and normal cells. In both these respects, the immune system is an attractive therapeutic approach. The immune system has multiple complementary effector mechanisms capable of killing target cells. Of these effector mechanisms, T cells can generate tumor antigen-specific immune responses because they have a vast array of clonally distributed antigen receptors, which can recognize tumor-specific antigens. It is well established that T cells recognize peptide fragments of cellular proteins bound to major histocompatibility complex (MHC) molecules on the surfaces of cells, and any cellular protein (including those from which tumor antigens are derived) can be presented to T cells in this way. Antigenspecific immunotherapy has been implemented in ovarian cancer treatment in human clinical trials such as HER-2/neu, MUC-1, NY-ESO-1 and CA-125. 4 Thus, cancer immunotherapy aimed at enhancing the function of antigen-specific T cells represents a rational treatment approach.
The identification of tumor-associated antigens uniquely expressed in ovarian cancer is also an important step for the development of effective immunotherapeutic strategies to control ovarian cancer. Mesothelin has been identified as an antigen that is highly expressed in a majority of ovarian cancers, 5 but has low expression in mesothelial cells lining the pleura, pericardium and peritoneum, 6 making it a potentially valuable target for the development of ovarian cancer vaccines and immunotherapeutic strategies. The mesothelin gene encodes a 69-kDa precursor protein that is processed to a 40-kDa membrane-bound protein called mesothelin and a 31-kDa shed fragment termed, megakaryocytepotentiating factor that is secreted from the cell. 6 The development of ovarian cancer vaccines and immunotherapeutic strategies requires a suitable preclinical model. The ovarian cancer tumor model, MOSEC, which is derived from mouse ovarian surface epithelial cells, has previously been shown to be capable of generating ascites and tumor growth in C57BL/6 mice receiving intraperitoneal tumor challenge. 7 Furthermore, the morphology of MOSEC tumor cells resembles ovarian serous carcinoma. Thus, the MOSEC ovarian cancer model serves as a potentially suitable preclinical model for testing ovarian cancer vaccines.
In the current study, we have created a luciferaseexpressing MOSEC (MOSEC/luc) tumor model that has allowed us to quantitate the distribution and tumor load in tumor-challenged mice using the non-invasive bioluminescence imaging system. In addition, we characterized the expression of murine mesothelin in the MOSEC/luc tumor model. We also determined that MOSEC/luc is endogenously processed and presented the murine mesothelin cytotoxic T lymphocyte (CTL) epitope (amino acid (aa) 406-414). Furthermore, we showed that adoptive transfer of mesothelin peptide (aa406-414)-specific CD8 + T cells led to the control of MOSEC/luc tumor cells. The generation of MOSEC/luc and the identification of murine mesothelin peptide aa406-414 as an H-2D b -restricted CTL epitope serve as a good foundation for the development of antigen-specific immunotherapies for ovarian cancer as well as quantitative mesothelin-specific CD8 + T cell immunological assays.
Results
Generation and characterization of an ascitogenic luciferase-expressing ovarian cancer cell line, MOSEC/luc One of the major challenges for the development of preclinical ovarian cancer models is the quantitative measurement of tumor growth in the peritoneal cavity. In order to create a suitable preclinical ovarian cancer model that is capable of forming ascites and expressing luciferase, we transduced an ovarian cancer cell line, MOSEC, with a retrovirus expressing firefly luciferase (MOSEC/luc). This would enable us to quantitate the tumor load using luciferase imaging. To determine if mice challenged with MOSEC/luc would generate ascites and sufficient luciferase activity for bioluminescence imaging, we challenged C57BL/6 mice, intraperitoneally, with MOSEC/luc tumor cells (5 Â 10 6 cells/ mouse). The luciferase expression was characterized using the non-invasive bioluminescence imaging system. As demonstrated in Figure 1a , mice intraperitoneally challenged with MOSEC/luc tumor cells were capable of developing significant ascites 8 weeks after the tumor challenge. In addition, the mice showed detectable luciferase expression in the peritoneal cavity 8 weeks after the tumor challenge (Figure 1c ). In contrast, C57BL/ 6 mice without MOSEC/luc tumor challenge did not show increased abdominal girth (Figure 1b ) or luciferase expression (Figure 1d ) in the peritoneal cavity. Thus, our data indicated that we successfully generated an ascitogenic luciferase-expressing MOSEC tumor cell line (MOSEC/luc) that would allow us to quantitate tumor load and distribution of MOSEC tumor cells in tumorchallenged mice using non-invasive bioluminescence imaging.
Murine mesothelin is highly expressed in MOSEC/luc tumor cells
Mesothelin has become a potentially ideal target for developing cancer vaccines against ovarian cancer(s) because it is highly expressed in ovarian cancer cells and is absent or expressed at low levels in normal cells. In order to determine whether MOSEC/luc tumor cells also express murine mesothelin, we characterized mesothelin expression in MOSEC/luc tumor cell line by reverse transcription polymerase chain reaction (RT-PCR) and flow cytometry analysis. As shown in Figure 2a , mRNA expression of murine mesothelin was detected in MOSEC/luc tumors but not in dendritic cells (DCs). 8 In addition, we performed quantitative real-time RT-PCR. As shown in Table 1 , gene expression of mesothelin is undetectable in DCs. In contrast, a significant high level of murine mesothelin expression was detected in MOSEC/luc. The mRNA expression ratio of mesothelin:b-actin was 0.01342. We also performed flow cytometry analysis using rat sera acquired from rats vaccinated with effective DNA vaccine encoding murine mesothelin. As there are no commercial mouse mesothelin antibodies available, we have created mesothelin-specific antibody using sera from rat vaccinated with DNA encoding murine mesothelin as described in the Materials and methods. As demonstrated in Figure 2b , mesothelin expression was detected in MOSEC/luc cells but not in DCs. These data indicated that murine mesothelin is highly expressed in MOSEC/luc tumor cells.
The murine mesothelin peptide aa406-414 contains a CD8 + CTL epitope
To identify murine mesothelin-specific CD8 + T-cell epitopes, we initially used the Bioinformatics & Molecular Analysis Section (BIMAS) 9 to predict for candidate murine MHC class I-restricted murine mesothelinspecific CTL epitopes (see Figure 3a) . We next determined which of these epitopes represented the true mesothelin-specific CD8 + T-cell epitopes using synthetic + T-cell responses, and elicits potent antitumor effects against an E7-expressing tumor model in vaccinated mice. 10 Splenocytes from vaccinated mice were harvested 1 week after the last vaccination and were stimulated with each of the various candidate mesothelin CTL peptides ( Figure 3a ). As shown in Figure  3b , splenocytes stimulated with mesothelin peptide aa406-414 generated the highest number of interferon (IFN)-g-secreting CD8 + T cells compared to those stimulated with the other candidate peptides. These data indicate that the murine mesothelin peptide aa406-414 is a mesothelin-specific CD8 + T-cell epitope.
Generation and characterization of a murine mesothelin peptide (aa406-414)-specific CD8 + T cell line
We generated a murine mesothelin (aa406-414)-specific CD8 + T cell line by repeatedly stimulating splenocytes from the mesothelin DNA-vaccinated mice with mesothelin aa406-414 peptide. To determine whether the CD8+ T cell line is indeed mesothelin (aa406-414)-specific, the CD8+ T cell line was incubated with either mesothelin peptide aa406-414 or irrelevant E7 peptide aa49-57. As shown in Figure 4a , murine mesothelin aa406-414 peptide was able to activate the CD8 + T cells to release IFN-g. In contrast, the control E7 aa49-57 failed to activate the CD8 + T cells. These data suggest that the CD8 + T cell line was murine mesothelin (aa406-414)-specific. We also confirmed that the CD8 + T cell line was a murine mesothelin-specific CD8 + T cell line using peptide-loaded MHC class I tetramer staining. As shown in Figure 4b , whereas the CD8 + T cells can be specifically detected by peptide-loaded H-2D b tetramer, the CD8 + T cells cannot be detected by E7 peptide-loaded H-2D b tetramer. Taken together, these findings indicate that we have successfully generated a H-2D b -restricted murine mesothelin peptide (aa406-414)-specific CD8 + T cell line.
Murine mesothelin (aa406-414)-specific CD8 + T cells can effectively kill MOSEC/luc tumor cells in vitro
The generation of a murine mesothelin (aa406-414)-specific CD8 + T cell line will allow us to determine whether the identified murine mesothelin-specific CD8 + T-cell epitope (mesothelin aa406-414) is naturally processed and presented by cells expressing mesothelin. In order to analyze quantitatively whether the mesothelin peptide-specific CD8 + T cells can specifically lyse the target cells loaded with mesothelin peptide, we transduced DCs with a retrovirus expressing firefly luciferase (DC/luc). This cell line allowed us to characterize CTL activity using non-radioactive bioluminescence imaging. The specific lysis of DC/luc would lead to the loss of luciferase activity. To demonstrate that murine mesothelin (aa406-414)-specific CD8 + T cells can specifically lyse mesothelin peptide-loaded DC/luc, we incubated the T cells with DC/luc pulsed with or without murine mesothelin aa406-414 peptide at different E/T ratios. As shown in Figure 5a , while the murine mesothelin Mesothelin-specific ovarian cancer immunotherapy C-F Hung et al (aa406-414)-specific CD8 + T cell line was able to kill DC/ luc pulsed with murine mesothelin peptide aa406-414, the CD8 + T cell line was not able to lyse the DC/luc without peptide or DC/luc pulsed with irrelevant E7 peptide aa49-57 (data not shown). Furthermore, when the T cell line was incubated with the MOSEC/luc tumor cells, they were able to specifically lyse the MOSEC/luc tumor cells (Figure 5b ). These data indicate that murine mesothelin-specific CTL epitope (mesothelin aa406-414) is naturally processed and presented by the mesothelinexpressing tumor cells.
Adoptive transfer of murine mesothelin (aa406-414)-specific CD8 + T cells led to the control of MOSEC/luc tumor cells in vivo
We further assessed whether adoptive transfer of mesothelin (aa406-414)-specific CD8 + T cells could lead to the control of MOSEC/luc tumors in vivo. C57BL/6 mice were challenged with MOSEC/luc tumors and then treated by injection with mesothelin (aa406-414)-specific CD8 + T cells intraperitoneally. Mice without CD8 + T-cell treatment were used as a control. Luciferase imaging was performed following the tumor challenge. As shown in Figure 6 , whereas mice without treatment with mesothelin peptide-specific CD8 + T cells continued to show tumor growth as indicated by luciferase expression, mice treated with murine mesothelin (aa406-414)-specific CD8 + T cells showed a significant reduction of tumor growth as demonstrated by the decrease in luciferase activity. Furthermore, tumor-challenged mice treated with mesothelin-specific T cells survived much longer than tumor-challenged mice without mesothelin specific T-cell treatment (Po0.05) (Figure 6c ). These data indicate that the adoptive transfer of murine mesothelin (aa406-414)-specific CD8 + T cells is able to control the MOSEC/ luc tumors in vivo.
Discussion
In the current study, we have created a mesothelinpositive luciferase-expressing murine ovarian cancer model, MOSEC/luc. We demonstrated that MOSEC/ luc endogenously processed and presented the murine mesothelin CTL epitope (aa406-414) and serves as a suitable preclinical ovarian cancer model for the characterization of therapeutic effects using non-invasive bioluminescence imaging. Additionally, this MOSEC/luc tumor model and the identified murine mesothelin CTL epitope will facilitate the development of immunotherapy for ovarian cancer and quantitative CD8 + T-cellmediated immunological assays.
There are several quantitative CD8 + T-cell-mediated immunological assays that are commonly used for the characterization of antigen-specific immune responses. Mesothelin-specific ovarian cancer immunotherapy C-F Hung et al
These assays include intracellular cytokine staining, ELISPOT, and peptide-loaded MHC class I tetramer staining. Among these assays, tetramer staining requires the identification of an MHC class I-restricted CTL epitope. Our newly identified H-2D b -restricted murine mesothelin-specific CTL epitope (aa406-414) has allowed us to generate a mesothelin peptide-loaded H-2D b tetramer, which we used to characterize a mesothelin peptide-specific CD8 + T cell line (Figure 4) . These assays will be very useful for the characterization of mesothelinspecific immune responses generated by various antigenspecific vaccines targeting mesothelin.
One of the major limitations to ovarian cancer immunotherapy is the difficulty of generating ovarian cancer mouse models. Without suitable ovarian cancer models in immune intact mice, it will be difficult to test new therapies for ovarian cancers. Mouse ovarian surface epithelial cells (MOSEC), in immune intact mice were developed by Roby et al. 7 MOSEC ovarian cancer cells were created by isolation of mouse ovarian surface epithelial cells and in vitro culture for more than 20 passages. Injection of these cells into the peritoneal cavity of immune intact mice resulted in the formation of ascitic fluid and multiple tumor implants. In addition, a more aggressive ovarian cancer line, Defb29Vegf was generated by stable transfection of VEGF and defensin in the MOSEC cell line. 11 Furthermore, primary mouse ovarian surface epithelial cells deficient in p53 and any two of the oncogenes c-myc, K-ras and Akt were sufficient to induce ovarian tumor formation when these cells were injected into mice. 12 Similarly, primary mouse ovarian surface epithelial cells deficient in p53 and Brca1 with Myc were also sufficient to induce transformation of ovarian cells. 13 A spontaneously occurring ovarian cancer mouse model, the Mullerian Inhibitory Substance type II Receptor (MISIIR) transgenic mice, has recently been generated. 14 The MISIIR transgenic mice that express the transforming region of SV40 under the control of the Mullerian inhibitory substance type II receptor gene promoter are capable of developing bilateral ovarian tumors. The MISIIR transgenic mice have been shown to develop ovarian carcinomas spontaneously within 6 to 13 weeks after birth.
14 Another transgenic mouse that expresses oncogenic K-ras and conditional Pten deletion within the ovarian surface epithelium has been shown to lead to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas. 15 The newly created MOSEC/luc tumor model will serve as an important model for the characterization of tumor load and distribution in tumor-challenged mice using non-invasive bioluminescence imaging. Previous studies also validate the use of luminescence imaging system for quantitatively measuring tumor load in vivo. [16] [17] [18] [19] Thus, the bioluminescence imaging used in this study represents a plausible non-invasive approach to measure tumor load and distribution in mice. However, a potential concern related to retrovirus transduction is the difference in expression of MHC class I molecules between MOSEC and MOSEC/luc cells. This may influence the interpretation of the data. We found that both the cell lines express comparable levels of MHC class I molecules (data not shown). Another potential issue is that MOSEC/luc cells may generate immune responses against luciferase because luciferase is a foreign protein to the mice. This may lead to regression of MOSEC/luc tumors when injected in mice. However, this is probably unlikely because the growth rates of MOSEC and MOSEC/luc in C57BL6 mice are comparable (data not shown).
Although we have demonstrated that the murine mesothelin aa406-414 represents a mesothelin-specific CTL epitope, we do not know if it is an immunodominant CTL epitope. Thus, it will be crucial for us to further characterize additional mesothelin-specific CTL epitopes and to determine the immunodominant epitopes for murine mesothelin. This information is important for the Mesothelin-specific ovarian cancer immunotherapy C-F Hung et al future development of effective mesothelin-specific vaccines. Further characterization of mesothelin-specific CTL epitopes using overlapping peptides covering the full-length of murine mesothelin protein may allow us to identify additional mesothelin-specific CTL epitopes. Several studies have employed this approach to identify antigen-specific CTL epitopes successfully. 20, 21 Our study describes the identification of a murine mesothelin-specific CTL epitope. This is the first time a murine mesothelin-specific CTL epitope has been identified in mouse ovarian cancer. Previous studies by us and others have identified several human mesothelin CD8 + Tcell epitopes. For instance, we have recently identified two HLA-A2-restricted human mesothelin-specific CD8 + T-cell epitopes using HLA-A2 transgenic mice. 22 One of these CTL epitopes, aa540-549, was also recently identified using peripheral blood mononuclear cells (PBMCs) derived from ovarian or pancreatic cancer patients. 23 In another study, HLA-A2-restricted mesothelin-derived peptides 20-28 and 530-538 were identified as CTL epitopes. 24 These human mesothelin CTL epitopes will be useful for the development of quantitative T-cell immunological assays that are important for the characterization of mesothelin-specific CD8 + T-cell immune responses in patients with mesothelin-expressing ovarian cancer.
Materials and methods
Mice C57BL/6 mice were acquired from the National Cancer Institute (Bethesda, MD, USA). All animals were maintained under specific pathogen-free conditions, and all procedures were performed according to approved Mesothelin-specific ovarian cancer immunotherapy C-F Hung et al protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Cell lines
The MOSEC cell line 7 and DC line 8, 25 were prepared as described previously. The DC line has been shown to express high levels of MHC class I and class II molecules, the costimulatory molecules B7-1 and B7-2, CD32, CD54, CD40, Mac-1 and the most specific marker, DEC-205. 8, 25 MOSEC-luciferase (MOSEC/luc) and dendritic cell-luciferase (DC/luc) were generated by transducing MOSEC and DCs with a retrovirus containing luciferase. In order to generate a retrovirus containing luciferase, a pLucithy1.1 construct expressing both luciferase and thy1.1 was made. Firefly luciferase was amplified by PCR from pGL3-basic (Promega) using the 5 0 primer CGGAGATC TATGGAAGACGCCAAAAAC and the 3 0 primer CGGGTTAACTTACACGGCGATCTTTCC. The amplified luciferase cDNA was inserted into the BglII and HpaI sites of the bicistronic vector pMIG-thy1.1. Both luciferase and thy1.1 cDNA are under the control of a single promoter element and separated by an internal ribosomal entry site (IRES). The pLuci-thy1.1 was transfected into Phoenix packaging cell line and the virion-containing supernatant was collected 48 h after transfection. The supernatant was immediately treated using a 0.45-mm cellulose acetate syringe filter (Nalgene, Rochester, NY, USA) and used to infect MOSEC and DCs in the presence of 8 mg/ml Polybrene (Sigma, St Louis, MO, USA). MOSEC/luc and DC/luc cells were sorted using preparative flow cytometry of stained cells with Thy1.1 antibody (BD, Franklin Lakes, NJ, USA).
Plasmid DNA constructs and DNA preparation
For the generation of plasmid encoding murine mesothelin, pcDNA3-meso, the DNA fragment encoding mesothelin, was first amplified in RT-PCR. RNA was extracted from the MOSEC cell line by TRIZOL (Invitrogen, Carlsbad, CA, USA). RT-PCR was performed using the Superscript One-Step RT-PCR Kit (Invitrogen, Carlsbad, CA, USA) and a set of primers: 5 0 -cccgaattcatggccttgccaacagctcga-3 0 and 5 0 -tatggatccgctcag ccttaaagctgggag-3 0 . The amplified product was then digested with EcoRI and HindIII and further cloned into the vector pcDNA3.1/myc-His(À) (Invitrogen, Carlsbad, CA, USA). The DNA was amplified in Escherichia coli DH5 and purified as described previously.
26
Quantitative real-time RT-PCR Before first-strand cDNA synthesis, RNA samples were treated with deoxyribonuclease I (Invitrogen, Carlsbad, CA, USA) to eliminate DNA contamination. RT-PCR was performed with oligo(dT) primer and M-MLV Reverse Transcriptase (Invitrogen) according to manufacturer's protocol. Then, we used the first-strand cDNA for realtime PCR, which was performed with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) on MyiQ realtime PCR detection system (Bio-Rad) according manufacture's protocol. The forward primer for mouse mesothelin is TTGGGTGGATACCACGTCTG; the reverse primer is CGGAGTGTAATGTTCTTCTGTC. We used beta-actin as the reference gene. The forward primer for beta-actin is CCCTAAGGCCAACCGTGAA and the reverse primer is GAGCATAGCCCTCGTAGAT.
DNA/siRNA vaccination
Gene gun particle-mediated DNA/siRNA vaccination was done using a helium-driven gene gun (Bio-Rad, Hercules, CA, USA) according to the protocol for RNA vaccination provided by the manufacturer, with a slight modification. Briefly, DNA/siRNA-coated gold particles were prepared by combining 25 mg of 1.6 mm gold microcarriers (Bio-Rad), 50 mg of plasmid DNA (50 ml), 5 mg of siRNA (50 ml), and 10 ml of 3 mol/l sodium acetate. Isopropyl alcohol (200 ml) was added to the mixture dropwise while mixing by vortex. This mixture was allowed to precipitate at room temperature for 10 min. The microcarrier/DNA/siRNA suspension was then centrifuged (10 000 r.p.m. for 30 s) and washed three times in fresh absolute ethanol before resuspending in 3 ml polyvinylpyrrolidone (0.1 mg/ml, Bio-Rad) in absolute ethanol. The solution was then loaded into 2.5 ft of gold-coated tube (Bio-Rad) and allowed to settle for 10 min. The ethanol was gently removed, and the microcarrier/DNA/siRNA suspension was evenly attached to the inside surface of the tube by rotation. The tube was then dried by 0.4 l/min of flowing nitrogen gas. The dried tube coated with microcarrier/DNA/siRNA was then cut to 0.5 inches cartridges and stored in a capped dry bottle at 41C. The DNA/siRNA-coated gold particles (1 mg DNA and 0.1 mg siRNA per bullet) were delivered to the shaved abdominal region of the mice using a helium-driven gene gun (Bio-Rad) with a discharge pressure of 400 p.s.i. C57BL/6 mice were immunized with 2 mg of the pcDNA3 plasmid encoding murine mesothelin and mixed with 0.2 mg BAK+BAX siRNA or control siRNA. The mice received three boosters with the same dose 1 week later. siRNAs were synthesized using 2 0 -O-ACE-RNAphosphoramides (Dharmacon, Lafayette, CO, USA). The sequences of BAK, BAX and control RNAi were described previously. 10 Generation of an E7 mesothelin-specific CTL cell line We used methods described previously to generate the mesothelin-specific CTL cell line. 27 Six-week-old female C57BL/6 mice were immunized four times by 2 mg of the pcDNA3 plasmid encoding murine mesothelin and mixed with 0.2 mg BAK+BAX siRNA. Splenocytes were harvested on day 7 after the last vaccination. For initial in vitro stimulation, 5 Â 10 6 splenocytes were pulsed with IL-2 at a concentration of 20 U/ml and 1 mg of mesothelin peptide (aa406-414) for 7 days. Propagation of the mesothelin-specific CTL cell line was performed in 24-well plates by mixing (2 ml/well) 1 Â 10 6 splenocytes containing mesothelin-specific CTLs with 3 Â 10 6 irradiated splenocytes and pulsing them with IL-2 at a concentration of 20 U/ml and 1 mg of mesothelin peptide (aa406-414). This procedure was repeated every 7 days.
Intracellular cytokine staining and flow cytometry analysis
Cell surface marker staining for CD8 and intracellular cytokine staining for IFN-g as well as flow cytometry analysis were performed under conditions described previously. 26 Splenocytes were harvested from mice 1 week after the last vaccination. For detecting mesothelinspecific CD8 + T-cell precursors, 5 Â 10 6 pooled splenocytes from each vaccination group were incubated for Mesothelin-specific ovarian cancer immunotherapy C-F Hung et al 16 h with either 1 mg/ml mesothelin peptide 406-414(GQKMNAQA1) or other peptides containing an MHC class I epitope based on Bioinformatics & Molecular Analysis Section (BIMAS) 9 (in Figure 3a) . Analysis was performed on a Becton-Dickinson FACSCalibur with CELLQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA, USA). For tetramer staining of a murine mesothelin-specific CD8 + T cell line, the murine mesothelin peptide (aa406-414)-loaded H-2D b tetramer (purchased from Beckman Coulter, San Diego, CA, USA) was used to stain for murine mesothelin peptide (aa406-414)-specific CD8 + T cells (from NIH). The E7-peptide-loaded H-2D b tetramer was used as a negative control.
Cytolytic activity assay
A non-radioactive method for cytolytic activity assay that utilizes luciferase to measure target cell viability was performed. 28 Target cells were luciferase-expressing dendritic cell line (DC/luc) with or without pulsing with mesothelin-specific peptide aa406-414, or luciferase-expressing MOSEC cell line (MOSEC/luc). The target cells were plated at a concentration of 10 000 cells per 0.1 ml/well in 96-well microplates. The cells were then co-cultured with increasing amounts of mesothelinspecific CD8 + T cells (in a final volume of 0.2 ml/well) at 371C for 6 h. A final concentration of 0.14 mg/ml luciferin (Promega, Madison, WI, USA) was added to each well, the plate was dark adapted for 10 min at 371C, and luminescence was read on the IVIS Imaging System Series 200 (Xenogen, Cranbury, NJ, USA). Cytolytic activity was determined by measuring the number of viable luciferase positive cells remaining following incubation with effectors. The percentage of lysis was calculated from the following equation: 100 À ½100ÂðA À BÞ=ðC À BÞ where A is the reading of photon counts for experimental cells, B is the background photon counts determined by plating target cells in media with a final concentration of 1% sodium dodecyl sulfate, C is the maximum photon counts determined by plating target cells in media without effector cells.
Treatment of mice with mesothelin-specific CD8 + T cells
To determine the direct effects of mesothelin-specific CD8 + T cells on the growth of MOSEC/luc tumors, two groups of mice were challenged with 2 Â 10 5 MOSEC/luc tumors by intraperitoneal injection. One group (five mice) was intraperitoneally treated with 2 Â 10 6 mesothelin (aa406-414)-specific CD8 + T cells and the other group (five mice) was treated with 1 Â phosphate-buffered saline (PBS) 1 day after MOSEC/luc challenge intraperitoneally. Tumor images were then measured using the IVIS Imaging System Series 200 (Xenogen). Bioluminescence tumor images were taken 1 day after MOSEC/luc challenge and 4 days after the transfer of mesothelin (aa406-414)-specific CD8 + T cells. To detect bioluminescence signals, mice were injected with 300 ml of 15 mg/ ml luciferin (Promega) intraperitoneally. Mice were imaged using the IVIS Imaging System Series 200 (Xenogen) 10 min after luciferin injection. Bioluminescence signals were acquired for 3 min. The survival of the tumor-challenged mice with or without T-cell treatment was also followed.
Statistical analysis
All data expressed as means 7s.d. are representative of at least two different experiments. Data for intracellular cytokine staining with flow cytometry analysis were evaluated by analysis of variance. Comparisons between individual data points were made using a Student's ttest. For the survival analysis of tumor-challenged mice receiving T-cell treatment, the Kaplan-Meier method and the log-rank statistic were used. All Po0.05 were considered significant.
